A5007683245- HER2/EGFR in Cancer Research
- Biosimilars and Bioanalytical Methods
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Women's cancer prevention and management
- Global Cancer Incidence and Screening
- Adrenal Hormones and Disorders
- Alkaloids: synthesis and pharmacology
- Prostate Cancer Treatment and Research
- Pituitary Gland Disorders and Treatments
- Palliative Care and End-of-Life Issues
- Economic and Financial Impacts of Cancer
- Prostate Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Cancer, Lipids, and Metabolism
- Cancer-related cognitive impairment studies
- Chemical synthesis and alkaloids
- Lymphatic System and Diseases
- Pharmacological Effects and Toxicity Studies
- Autopsy Techniques and Outcomes
- Phytochemistry Medicinal Plant Applications
- Cancer survivorship and care
- Schizophrenia research and treatment
Faculdade de Medicina do ABC
2004-2024
Hospital Estadual Mário Covas
2015-2024
Centro de Pesquisas Oncológicas
2018-2019
German Breast group
2018
Amgen (United States)
2018
Spitalul Clinic Județean de Urgență Cluj-Napoca
2018
Universidade Estadual Paulista (Unesp)
2016
Faculdade São Lucas
2015
Insper
2015
Instituto Brasileiro de Controle do Câncer
2014
The number of positive axillary lymph nodes involved by tumor is one the main prognostic factors for women with locoregional breast cancer (BC) whom adjuvant chemotherapy being considered. importance ratio (P/D) between (P) and total dissected (D), previously demonstrated in high-dose (HDC) setting has not yet been tested, however, conventional setting. data 168 patients who were from 2 institutions treated BC retrospectively analyzed, univariate multivariate analysis performed, including...
Cat's claw (Uncaria tomentosa) is a native Amazon plant that exhibits anti-inflammatory and antitumor properties. We wanted to assess its activity for symptom management of terminal cancer patients.This prospective phase II study assessed the effects 100-mg dose dry extract U. tomentosa three times per day in patients with advanced solid tumors who had no further therapeutic options life expectancy at least 2 months. The European Organization Research Treatment Cancer Quality Life...
to evaluate if time between surgery and the first adjuvant treatment (chemotherapy, radiotherapy or hormone therapy) in patients with breast cancer is a risk factor for lower overall survival (OS).data from five-year retrospective cohort study of all women diagnosed invasive at an academic oncology service were collected analyzed.three hundred forty-eight consecutive included. Time was shorter (HR=1.3, 95CI 1.06-1.71, p=0.015), along negative estrogen receptor, presence lymphovascular...
Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2(+)) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) capecitabine (C) regimen, evaluating L combined with other cytotoxic drugs, are warranted.In present phase II, multicenter study, patients HER2(+) MBC progression after taxane were randomized between L, 1250 mg, C, 2000 mg/m(2) on days 1 14 (LC),...
Objective: The objective of this study was to evaluate the safety using tegafur–uracil (UFT) in colorectal cancer patients with partial dihydropyrimidine dehydrogenase (DPD) deficiency. Patients and Methods: included five who presented acute toxicity (grades 3 4) after being given first cycle chemotherapy 5-fluorouracil. DPD deficiency confirmed by gene sequencing. After a full recovery from all side effects, we changed regimen UFT (300 mg/m 2 /day) associated leucovorin (90 mg/day) for 21...
Although the human epidermal growth factor receptor 2 (HER2) blocker trastuzumab is generally well tolerated, cardiotoxicity can be an important therapeutic limitation. In this prespecified analysis, we compared cardiac safety of biosimilar ABP 980 (KANJINTI™) and reference product (RP; Herceptin®) in phase III LILAC study (ClinicalTrials.gov identifier NCT01901146). neoadjuvant LILAC, after run-in chemotherapy, 725 patients were randomized 1:1 to (n = 364) or RP 361) plus paclitaxel (every...
To evaluated whether Paullinia cupana decrease number and severity of hot flashes in breast cancer survivors.This was a prospective phase II pilot study. We studied female survivors who had completed the treatment 3 months previously were experiencing at least 14 per week. At 9 15 patients required to have 50% flash score keeping with Simon Design. Patients received 50mg dry extract orally twice day for 6 weeks. assessed both frequency flashes.A total 18 started treatment, Three left study...
Complete androgen blockade (CAB) does not prolong overall survival (OS) in patients with castration refractory prostate cancer (CRPC). Although there is variable clinical benefit second-line hormone manipulation, we do know which might the most.To identify predictors of complete blockade.We reviewed records for 54 who received treatment CAB setting disease progression despite castration. We evaluated progression-free (PFS) and OS according to PSA at diagnosis, Gleason scores, age,...
Abstract Background: Analytical, functional, and pharmacokinetic similarity between ABP 980 trastuzumab (TRAS) has been demonstrated. Here we report results from the single switch treatment arm in adjuvant phase of corresponding clinical study. Methods: The objective this randomized, multicenter, double-blind study was to compare with TRAS women HER2-positive early breast cancer. After run-in anthracycline-based chemotherapy, patients were randomized 1:1 intravenous or plus paclitaxel Q3W...
Abstract Disclosure: T.D. Bertolacini da Silva: None. V.D. Kamura: P.D. Buchalla: A.G. Simoes: S. Glina: Z.M. Campos: I.S. Rosa: P.X. Santi: Background: The association of dependent Cushing's ACTH Syndrome with certain types cancer is well known, such as small cell lung cancer, enteropancreatic tumors, thymoma, thyroid however, in cervical there are almost no cases described. Clinical Case: A 39-year women, showed about 2.5 years ago abnormal uterine bleeding, being submitted to colposcopy...
Abstract Disclosure: T.D. Bertolacini da Silva: None. V.D. Kamura: P.D. Buchalla: A.G. Simoes: S. Glina: Z.M. Campos: I.S. Rosa: P.X. Santi: Background: The association of dependent Cushing's ACTH Syndrome with certain types cancer is well known, such as small cell lung cancer, enteropancreatic tumors, thymoma, thyroid however, in cervical there are almost no cases described. Clinical Case: A 39-year women, showed about 2.5 years ago abnormal uterine bleeding, being submitted to colposcopy...
583 Background: The phase 3 LILAC Study compared ABP 980 with trastuzumab (TRAS) on pathologic complete response (pCR) in women HER2+ early breast cancer. primary efficacy results, based local laboratory evaluation of tumor samples, have been reported previously. Here we report the results pCR analysis central samples. Methods: After run-in anthracycline-based chemotherapy, patients were randomized 1:1 to or TRAS plus paclitaxel Q3W x 4 Q1W 12. co-primary endpoints risk difference (RD) and...
557 Background: Although trastuzumab is generally well-tolerated, cardiotoxicity the main limitation in its use, leading to a severe heart failure 2-4% of patients adjuvant trials. In phase 3 LILAC trial, biosimilar ABP 980 demonstrated similar efficacy, safety, and immunogenicity reference product (RP) women with HER2-positive early breast cancer. Here we report analyses comparing cardiac safety RP. Methods: neoadjuvant phase, all 725 received 4 cycles chemotherapy epirubicin +...
e17589 Background: Several studies showed that delays in the initiation of treatment since diagnosis breast cancer may lead to worse prognosis.The purpose this study was evaluate if time from surgery until first adjuvant (chemotherapy, radiotherapy or hormone therapy) patients with is a risk factor for lower overall survival (OS). Methods: Five-year retrospective cohort which data medical records all women diagnosed invasive attended at an academic oncology service were collected and...
9557 Background: Cat’s claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and antitumor properties. Methods: This prospective phase II study assessed the effects of 100-mg dose dry extract U. tomentosathree times per day on individuals with advanced solid tumors, no further therapeutic options at least 2 months life expectancy. We used EORTC QLQ C30 FACIT-F questionnaires to assess participants´ quality life, HADS questionnaire their anxiety depression...
Introduction: Surviving acute kidney (AKI) patients have a higher late mortality.The negative impact of malnutrition on the early outcome AKI has recently been confirmed by various studies.However, its after hospital discharge not studied.The objective study was to determine role anthropometric measurements and handgrip strength as predictors mortality 180 days discharge.Methodology: Ninety-five consecutive who were older than 18 y old followed team prospectively evaluated.Patient's...
6040 Background: The accrual rate of patients into cancer clinical trials has been consistently low. Among the barriers to trial enrolment, influence caregivers on patients’ decision participate scantily evaluated. We aimed understand perceptions patient enrollment trials. Methods: Caregivers three groups (40 survivors, 40 metastatic under chemotherapy treatment and who were receiving supportive care exclusively) completed a questionnaire about demographic data, their relationship with care,...
e20524 Background: Fatigue and Depression are common in patients undergoing Breast Cancer (BC) treatment. Catuama is a registered phytotherapic that contains 4 brazilian herbs per capsule: Trichilia catigua (87.5mg), Ptychopetalum olacoides Paullinia cupana (125 mg) Zingiber officinale (10mg). Objectives: Since one of its constituents Guarana (Paulinia cupana) which we already reported to have anti-fatigue effects, decided test potential effects BC women adjuvant weeks Radiation Therapy...
Breast cancer is a public health problem with both high incidence and cure rates. After treatment, patients are monitored for long periods of time due to the risk recurrence. Thus, staging follow-up strategies should consider not only best results patient but also its costs system.The objective this study was quantify waste resources on breast evaluate impact system.This retrospective analysis consecutive medical records identify intervals between consultations tests used during first 2...
e16141 Background: Complete androgen blockade (CAB) after failure of castration or receptor blocker (ARB) has not shown to prolong survival in patients with metastatic prostate cancer, unlike docetaxel-based chemotherapy. The widely variable clinical benefit seen CAB as second-line hormone manipulation still justifies the identification whom it should be offered. Objective: evaluate progression-free (PFS) and overall (OS) treated ARB identify predictors benefit. Methods: We performed a...